Paras Healthcare Limited (PARASHLTH)

Paras Healthcare Limited announced the outcome of its Board Meeting held on November 05, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, accompanied by unmodified limited review reports from Walker Chandiok & Co LLP. Additionally, the Board approved the continuation of Mr. Kabir Kishin Thakur as Non-Executive Non-Independent Director under Regulation 17(1D), subject to shareholder approval. The specific financial performance tables were not included in this outcome text extract.

• Board approved unaudited financial results for the quarter and half year ended September 30, 2026
• Statutory auditor Walker Chandiok & Co LLP issued an unmodified Limited Review Report
• Approved continuation of directorship of Mr. Kabir Kishin Thakur (DIN: 08422362), liable to retire by rotation
• Board meeting commenced at 05:30 P.M. IST and concluded at 06:08 P.M. IST on November 05, 2026

Paras Healthcare Limited received a SEBI SAST Regulation 29(1) disclosure from 360 ONE entities (various series of Special Opportunities, Private Equity, and Equity Opportunity Funds). The funds hold 78,81,992 equity shares, representing 7.28% of the total and diluted share capital. The disclosure stems from the conversion of unlisted shares into listed shares following the company's IPO and listing on October 28, 2026.

• 360 ONE funds collectively hold 78,81,992 shares representing 7.28% voting capital
• Acquisition mode is unlisted shares conversion into listed shares on account of an IPO
• Date of acquisition/trigger event was the listing date on October 28, 2026
• Total post-acquisition equity share capital stands at 10,82,01,194 shares (diluted 10,85,00,790 shares)

Paras Healthcare Limited has submitted a disclosure under Regulation 30(5) of the SEBI Listing Regulations. The Board of Directors authorized four Key Managerial Personnel (KMPs) to determine materiality and report disclosures to the stock exchanges. Dr. Dharminder Kumar Nagar (MD), Dr. Kapil Garg (WTD), and Dilip Bidani (Group CFO) are authorized to determine materiality and make disclosures, while Rahul Kumar (CS) is authorized to make disclosures. This is a procedural statutory compliance update.

• Board authorized 4 Key Managerial Personnel under Regulation 30(5) of SEBI Listing Regulations
• 3 KMPs authorized to determine materiality: Managing Director, Whole Time Director, and Group CFO
• 1 KMP (Company Secretary & Compliance Officer) authorized specifically to make disclosures to stock exchanges
• Filing communicated to NSE and BSE on October 28, 2026

Paras Healthcare Limited submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) under Regulation 8(2) of the SEBI PIT Regulations. The code was formulated and approved by the Board of Directors in their meeting held on October 26, 2026. The policy sets guidelines on fair disclosure, digital database tracking with an 8-year record retention rule, and defines legitimate purposes for information sharing. This is a standard statutory governance disclosure that comes into force from the date of listing.

• Approved by the Board of Directors on October 26, 2026
• Code formulated pursuant to Regulation 8(1) and 8(2) of SEBI PIT Regulations
• Mandates maintenance and preservation of a structured digital database for not less than 8 years
• Company Secretary designated as the Chief Investor Relations Officer (CIRO)

Paras Healthcare Limited has submitted a regulatory disclosure pursuant to Regulation 7(1) of the SEBI Listing Regulations. The company confirmed the appointment of MUFG Intime India Private Limited (formerly Link Intime India Private Limited) as its Registrar to an Issue & Share Transfer Agent (RTA). This is a standard compliance filing and has no impact on operations, revenue, or profitability.

• Disclosure submitted pursuant to Regulation 7(1) of SEBI Listing Regulations
• Appointed MUFG Intime India Private Limited (formerly Link Intime India Private Limited) as RTA
• Filing officially signed and submitted on October 28, 2026
• Disclosure hosted on company website at parashospitals.com/investors

Paras Healthcare Limited has formally disclosed the appointment of Mr. Rahul Kumar as its Compliance Officer pursuant to Regulation 6(1) of the SEBI Listing Regulations. Mr. Kumar, who is also the Company Secretary and Key Managerial Personnel (KMP) holding ICSI Membership No. A20928, took on the role with effect from July 22, 2024. The filing serves as a standard statutory compliance disclosure submitted to the stock exchanges on October 28, 2026. This administrative update does not have any direct financial or operational impact on the company.

• Rahul Kumar appointed as Compliance Officer effective July 22, 2024
• Appointed under Regulation 6(1) of SEBI Listing Regulations
• Incumbent holds ICSI Membership No. A20928 and serves as Company Secretary/KMP
• Disclosure submitted to exchanges on October 28, 2026